Retina360 DME Management: Balancing the Burden With New Injectable Protocols is organized by Healio, Vindico Medical Education.
Release Date: August 31, 2023
Expiration Date: August 30, 2024
Activity Description:
Visual acuity outcomes in patients with diabetic macular edema (DME) receiving intravitreal anti-vascular endothelial growth factor (VEGF) therapies are often suboptimal compared with those seen in clinical studies. Discrepancies in outcomes have been associated with loss of patient adherence due to the treatment burden associated with frequent intravitreal injections. To redress the treatment burden, personalized treatment protocols and the approval of second-generation anti-VEGF therapies with extended durations of action are being integrated into treatment algorithms to reduce the frequency of injections while maintaining anatomical and visual outcomes. Extended-release corticosteroids, which offer longer intervals between dosing, are also an effective therapeutic option for patients with DME. However, these agents are often not effectively integrated into clinical management protocols. In this CE monograph, experts in the field guide how to integrate new evidence into practice regarding the efficacy, durability, and safety of injectable regimens. They also evaluate the use of early treatment regimens for patients with DME who have demonstrated reduced vision loss while lengthening intervals between injections.
Learning Objective:
Upon successful completion of this activity, participants should be better able to:
• Apply new evidence into practice regarding the efficacy, durability, and safety of injectable regimens approved for use in the treatment of DME.
• Implement the use of early treatment for DME with regimens that have been shown to reduce vision loss and lengthen intervals between injections.